novo nordisk insulin - Search News

Novo Nordisk Skeptic Finally Upgrades Stock

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

Markets Insider · 11h

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Bloomberg L.P. · 14h

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.

Reuters on MSN · 3d

Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall

Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks, but shares fell, likely on the lower-than-expected weight loss.

Fox Business on MSN · 3d

Novo Nordisk shares fall on weight-loss drug trial

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

NBC New York · 3d

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

STAT3d

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

Fierce Pharma3d

Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

3don MSN

Why Novo Nordisk Stock Is Falling Today

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Novo Nordisk, Sanofi Face South Africa Insulin Antitrust Probe

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

Novo Nordisk under pressure as obesity drug disappoints in diabetes trial

Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results